Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "25" vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hydrochlorothiazide is not extensively metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Reserpine: 95-98% bound to plasma proteins; hydrochlorothiazide: 60-70% bound to albumin.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Reserpine: Vd approximately 0.5-0.7 L/kg, indicating extensive tissue distribution and high lipophilicity; hydrochlorothiazide: Vd 0.2-0.4 L/kg, primarily confined to extracellular fluid.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Reserpine: oral bioavailability approximately 50% due to first-pass metabolism; hydrochlorothiazide: oral bioavailability 65-75%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 30-50 m L/min: 25 mg once daily. GFR 15-29 m L/min: not recommended. GFR <15 m L/min: contraindicated.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A or B: no adjustment. Child-Pugh Class C: use with caution, consider starting at 12.5 mg daily.
Child-Pugh Class B or C: contraindicated; use not recommended.
Weight-based: 1-2 mg/kg/day orally divided every 12-24 hours, maximum 100 mg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at 12.5 mg daily; monitor electrolytes and renal function; may increase to 25 mg daily if needed.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
May cause electrolyte imbalance (hypokalemia, hyponatremia),May exacerbate systemic lupus erythematosus,Reserpine may cause mental depression, peptic ulcer, and nasal congestion,Photosensitivity,Orthostatic hypotension with reserpine
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Anuria,Sulfonamide allergy (hydrochlorothiazide is a sulfonamide),Known hypersensitivity to hydrochlorothiazide or reserpine,Active peptic ulcer (due to reserpine),Electroconvulsive therapy (within 7 days, due to reserpine)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-sodium foods to enhance antihypertensive effect. Limit alcohol intake as it may potentiate hypotension. Grapefruit juice may alter drug metabolism; avoid excessive consumption. Maintain adequate potassium intake (bananas, oranges) unless advised otherwise by your doctor.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. In the second and third trimesters, exposure may cause fetal bradycardia, hypothermia, and respiratory depression due to depletion of catecholamines. Chronic use may lead to fetal growth restriction.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Reserpine is excreted into breast milk with an M/P ratio of 0.5. Due to the potential for serious adverse reactions in nursing infants, including gastrointestinal disturbances, nasal congestion, and lethargy, breastfeeding is contraindicated during reserpine therapy.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No pharmacokinetic studies are available to guide dosing adjustments during pregnancy; however, due to increased plasma volume and renal clearance, the effective dose may need to be increased, but this must be balanced against fetal risks. The lowest effective dose should be used and the drug should be discontinued if possible, especially during the third trimester to avoid neonatal effects.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Hydro-Serp '25' contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause mental depression; use with caution in patients with history of depression. Taper reserpine before surgery to avoid hypertensive rebound. Avoid concurrent use with MAOIs.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not discontinue abruptly.,This medication may make you dizzy or drowsy; avoid driving until you know how it affects you.,Rise slowly from sitting or lying to prevent falls from low blood pressure.,Report any mood changes, depression, or vivid dreams to your doctor.,Use sunscreen and protective clothing; this drug increases sun sensitivity.,Do not use potassium supplements or salt substitutes without asking your doctor.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "25" vs ALDORIL D30, answered by our medical review team.
HYDRO-SERP "25" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "25" and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "25" is: Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "25" and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "25" is classified as Category C. FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.